Home›Neurology› Shared molecular pathways and hub genes link endocrine disorders with periodontitis progression
Shared molecular pathways and hub genes link endocrine disorders with periodontitis progressionShared Molecular Pathways Link Endocrine Disorders and Periodontitis
Frontiers in MedicinePublished July 18, 2026Study authors: Mireya Martínez-García, Enrique Hernández-LemusDOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that shared molecular pathways like NF-kB and NLRP3 inflammasome drive crosstalk between endocrine disorders and periodontitis.
This narrative review explores the molecular architecture underlying the interaction between endocrine disorders and periodontitis. The authors synthesize evidence regarding common signaling pathways that may drive both conditions simultaneously.
The review identifies several key mechanisms of crosstalk, including NF-kB activation, NLRP3 inflammasome-driven IL-1 and IL-18 maturation, cytokine network dysregulation, oxidative stress amplification, and RANKL/OPG imbalance. Additionally, the authors identify specific hub genes—TNF, IL6, LEP, NOS3, STAT3, and VEGFA—as central nodes in endocrine and periodontal signaling. The review also highlights enriched molecular routes such as PI3K/Akt, AGE-RAGE, JAK-STAT, Th17 differentiation, and HIF-1 pathways.
A primary limitation of this synthesis is that it is a narrative review of existing evidence rather than an analysis of primary data. Consequently, the potential therapeutic efficacy of mentioned pharmacological agents like GLP-1 receptor agonists or statins is based on mechanistic grounds rather than clinical trial results in this text. The findings suggest that interdisciplinary models may be useful for managing patients with comorbid endocrine disorders and periodontitis due to their shared molecular architecture.
How this fits prior evidence
This narrative review addresses a gap by identifying the specific molecular pathways, such as NF-kB activation and NLRP3 inflammasome activity, that link endocrine disorders and periodontitis. While prior coverage noted that GLP-1 receptor agonists reduce HF worsening events in HFpEF and oral small-molecule GLP-1RAs reduce body weight and HbA1c, this review focuses on the shared biological mechanisms between endocrine and periodontal tissues rather than specific clinical outcomes for those medications.
A narrative review explored the complex relationship between endocrine disorders and periodontitis. Researchers looked at how these two conditions share similar molecular pathways. They identified specific markers like inflammation and oxidative stress that appear in both cases.
The study highlighted several key biological hubs, such as TNF and IL6, which play roles in both systems. These shared pathways involve the body's response to stress and immune system signals. By identifying these common links, researchers hope to better understand why patients with endocrine issues may also face gum health problems.
Because this is a narrative review of existing evidence rather than a new clinical trial, the results are not yet used to change standard medical practice. The findings suggest that doctors might eventually use more integrated models to treat patients who have both conditions. You should talk with your healthcare provider about how these biological links might affect your specific treatment plan.
What this means for you:
Research shows shared molecular pathways between endocrine disorders and gum disease, suggesting a link in their development.
Common questions
What is the link between endocrine disorders and gum disease?
The study identified several shared molecular pathways, such as NF-kB activation and oxidative stress. These mechanisms are involved in both endocrine systems and periodontal health. This suggests that the two conditions share common biological drivers like inflammation and immune system signals.
Are there specific genes involved in both conditions?
The review identified several hub genes that act as molecular nodes for both endocrine and periodontal signaling. These include TNF, IL6, LEP, NOS3, STAT3, and VEGFA. These genes are part of the shared pathways between the two conditions.
Does this mean a new treatment is available for these conditions?
This study was a narrative review of existing evidence rather than a clinical trial. While it identifies common biological mechanisms, it does not provide results from new drugs or specific treatments. You should consult your doctor regarding any changes to your current medical treatment.
Periodontitis is a chronic multifactorial inflammatory disease whose pathological consequences extend well beyond the oral cavity to affect systemic health through the dissemination of pro-inflammatory mediators, bacteremic episodes, and the amplification of low-grade systemic inflammation. Concurrently, the endocrine system functions as a central regulator of periodontal tissue homeostasis, with hormone receptors for estrogens, androgens, glucocorticoids, insulin, thyroid hormones, and vitamin D expressed across the principal cell populations of the periodontium, including gingival fibroblasts, PDL cells, osteoblasts, osteoclasts, and epithelial cells. This narrative review synthesizes current evidence on the molecular pathways mediating the bidirectional relationship between periodontal disease and endocrine imbalance, integrating experimental, clinical, and systems-level bioinformatics data to provide a comprehensive mechanistic framework for this interaction. We examine how estrogen deficiency, progesterone excess, androgen dysregulation, insulin resistance, adipokine imbalance, thyroid dysfunction, glucocorticoid excess or deficiency, and perturbations of the parathyroid hormone and vitamin D axes each contribute to periodontal susceptibility through distinct but convergent molecular mechanisms involving NF-B activation, NLRP3 inflammasome-driven IL-1 and IL-18 maturation, cytokine network dysregulation, oxidative stress amplification, and disruption of the RANKL/OPG balance governing alveolar bone homeostasis. We also discuss key hub genes including TNF, IL6, LEP, NOS3, STAT3, and VEGFA as molecular nodes that simultaneously participate in endocrine and periodontal signaling, and we highlight the PI3K/Akt, AGE-RAGE, JAK-STAT, Th17 differentiation, and HIF-1 pathways as the most significantly enriched molecular routes of endocrine-periodontal crosstalk. The RANKL/OPG axis emerges as a central integrator of hormonal and inflammatory inputs to alveolar bone metabolism, with estrogen, PTH, glucocorticoids, vitamin D, leptin, and adiponectin each converging on this molecular switch through receptor-mediated mechanisms that are additive to the inflammatory RANKL upregulation driven by IL-1, IL-6, IL-17, and TNF- in active periodontal lesions. Emerging pharmacological agents at the endocrine-periodontal interface, including GLP-1 receptor agonists, denosumab, statins, vitamin D supplementation, and specialized pro-resolving mediators, offer mechanistically grounded opportunities for integrated therapeutic strategies that address both oral and systemic disease simultaneously. The diagnostic and therapeutic implications of these molecular relationships demand a fundamental reorientation of clinical management toward interdisciplinary models in which periodontal assessment is incorporated into the evaluation of patients with endocrine disorders, endocrine status is systematically characterized in patients with severe or treatment-refractory periodontitis, and therapeutic decisions in both specialties are made with explicit awareness of the shared molecular architecture linking them.
